Sebastiano Buti

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 415 citations · Full text

Medicine, Immunology, Oncology +16

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli et al. · Clinical Cancer Research · 2019 · 239 citations · Full text

Medicine, Immunology, Oncology +17

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini, Sebastiano Buti, Daniele Santini et al. · The Oncologist · 2019 · 221 citations · Full text

Life Sciences, Immunology, Oncology +17

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Alessio Cortellini, Rita Chiari, Biagio Ricciuti et al. · Clinical Lung Cancer · 2019 · 179 citations

Life Sciences, Immunology, Oncology +16

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Robert J. Motzer, Paul Russo, Viktor Grünwald et al. · The Lancet · 2023 · 172 citations · Full text

Medicine, Oncology, Pharmacotherapy +10